Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide.

导出 LinkOut

翻译打印收藏纠错

作者： Mamta,Parikh ^[1] ; Catherine,Tangen ^[2] ; Maha H A,Hussain ^[3] ; Shilpa,Gupta ^[4] ; Sam,Callis ^[2] ; Yeonjung,Jo ^[5] ; Andrea,Harzstark ^[6] ; Channing J,Paller ^[7] ; Saby,George ^[8] ; Matthew R,Zibelman ^[9] ; Heather H,Cheng ^[10] ; Benjamin L,Maughan ^[5] ; Jingsong,Zhang ^[11] ; Russell K,Pachynski ^[12] ; Alan H,Bryce ^[13] ; Daniel W,Lin ^[10] ; David I,Quinn ^[14] ; Seth P,Lerner ^[15] ; Ian M,Thompson ^[16] ; Tanya B,Dorff ^[17] ; Primo N,Lara ^[18] ; Neeraj,Agarwal ^[5]

作者单位： UC Davis Comprehensive Cancer Center, Sacramento, CA, USA. Electronic address: mbparikh@ucdavis.edu. ^[1] SWOG Statistics and Data Management Center, Seattle, WA, USA. ^[2] Northwestern University, Chicago, IL, USA; Robert H Lurie Comprehensive Cancer Center, US. ^[3] Cleveland Clinic, Cleveland, OH, USA. ^[4] University of Utah, Salt Lake City, UT, USA. ^[5] Kaiser Permanente San Francisco Medical Center, San Francisco, CA, USA. ^[6] Johns Hopkins University, Baltimore, MD, USA. ^[7] Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. ^[8] Fox Chase Cancer Center, Philadelphia, PA, USA. ^[9] University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, USA. ^[10] Moffitt Cancer Center, Tampa, FL, USA. ^[11] Washington University School of Medicine in St. Louis, St. Louis, MO, USA. ^[12] City of Hope, Goodyear, AZ, USA. ^[13] USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA. ^[14] Baylor College of Medicine, Houston, TX, USA. ^[15] University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. ^[16] City of Hope Comprehensive Cancer Center, Duarte, CA, USA. ^[17] UC Davis Comprehensive Cancer Center, Sacramento, CA, USA. ^[18]

关键词 Biomarker Castration sensitive Hormone sensitive Prostate cancer Prostate-specific antigen

主题词人类(Humans);男(雄)性(Male);前列腺特异抗原(Prostate-Specific Antigen);甲苯磺酰化合物(Tosyl Compounds);酰苯胺类(Anilides);腈类(Nitriles);前列腺肿瘤(Prostatic Neoplasms);雄激素拮抗药(Androgen Antagonists);老年人(Aged);预后(Prognosis);中年人(Middle Aged);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);肿瘤转移(Neoplasm Metastasis);老年人, 80以上(Aged, 80 and over)

DOI 10.1016/j.euo.2024.03.001

PMID 38523017

发布时间 2024-10-23

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

European urology oncology

2024年7卷5期

1097-1104页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide.

European urology oncology

相似文献

European urology oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide.

European urology oncology

相似文献

European urology oncology

相关期刊

检索历史清除